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Abstract
Alzheimer's disease is a devastating illness that is 
common among the nursing home population. Treatment for 
Alzheimer's disease is usually palliative and consists of 
using psychotropic medications to control aggressive and 
agitated behaviors exhibited by its victims. The purpose 
of this descriptive study was to identify behaviors 
exhibited by Alzheimer's disease patients before and after 
receiving psychotropic medications. Johnson's Behavioral 
System Model was used as the theoretical framework for 
this study. The sample (N = 33) consisted of nursing home 
residents with a diagnosis of Alzheimer's disease who were 
treated with one psychotropic medication. The researcher 
used chart review to examine the behaviors exhibited by 
the patients and the psychotropic medication received.
Data were gathered using the Behavioral Assessment for 
Institutionalized Alzheimer's Patients. Data analysis 
consisted of descriptive statistics and t, tests to measure 
significant changes in behaviors. Six categories of 
measurement included memory/recall ability, cognitive 
skills for daily decision making, indicators of delirium- 
periodic disordered thinking/awareness, indicators of 
depression, anxiety, sad mood, and behavioral symptoms.
iii
Findings revealed significant changes in all areas 
measured. Conclusions derived from the study were that 
psychotropic medications significantly impact behaviors of 
the Alzheimer's disease patient. Recommendations include 
replication of the study with a larger sample, refinement 
of the tool utilized to measure behaviors, education of 
personnel regarding behaviors exhibited by the Alzheimer's 
disease patient, and comparison of the effects of 
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Psychotropic medications are among the most 
frequently prescribed pharmacological agents for America's 
elders. Originally designed to treat individuals with a 
history of documented illness, these drugs are useful when 
used appropriately. However, misappropriate use of 
psychotropic drugs has been documented by epidemiologic 
evidence in research (Sherman, 1994) .
Alzheimer's disease is the leading cause of serious 
mental illness in persons over the age of 65 years. Yet 
the most significant causes of cognitive impairment in 
Alzheimer's disease patients are not necessarily disease 
related but may be side effects of sedative/hypnotics and 
long-acting benzodiazepines (Sherman, 1994). Although 
psychotropic medications are indicated for mental illness 
in persons with Alzheimer's disease, these drugs are being 
used to control behavioral problems without adequate 
examination of the long-term cognitive effects (McShane & 
Keene, 1997; Yeager, Farnett, & Ruzicka, 1995).
Alzheimer's disease patients have more cognition, 
memory, and orientation problems as well as a generally 
more rapid mental decline with the use of psychotropic 
medications (McShane & Keene, 1997). Nevertheless 
psychotropic drugs have been used to control disruptive 
behavior and sleeplessness and, therefore, have become 
known as chemical restraints (Castle, 1999) . These drugs 
were originally designed to treat individuals with a 
history of documented mental illness and were not intended 
to treat individuals with symptoms of dementia (Sherman, 
1994).
Conversely, the increased sensitivity of the elderly 
to various drugs has been well established (McShane & 
Keene, 1997). Given the fact that half-life and clearance 
of many drugs may be altered in elders, routine use of 
psychotropic drugs among demented elders is questionable 
at best. These drugs not only alter behaviors but increase 
the risk for serious complications related to falls and 
hip fractures. Nurse practitioners in primary care and 
long-term care settings are often responsible for making 
decisions about instituting, altering, or discontinuing 
use of psychotropic drugs in clients with Alzheimer's 
disease. An empirical basis for making such decisions is 
needed. Therefore, the focus of this study was to evaluate
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the behaviors of institutionalized Alzheimer's disease 
patients before and after the initiation of psychotropic 
medications.
Establishment of the Problem
Dementia affects 5% of persons over the age of 65 
years and 20% of those over 80 years of age. The incidence 
of dementia is expected to increase as the population 
ages. Alzheimer's disease has been reported as the most 
common form of dementia and accounts for 70% of all 
nursing home admissions (Yeager et al., 1995) . Alzheimer's 
disease follows a specific pattern of cognitive losses and 
behavioral disturbances. The impact of Alzheimer's disease 
management has dramatic physical, psychological, and 
financial consequences for patients and caregivers 
(Corcoran & Gitlin, 1992). Agitated behaviors associated 
with Alzheimer's disease include aggression, irritability, 
and psychotic symptoms, including hallucinations and 
delusions. In addition, there is a progressive, 
irreversible loss of memory, deterioration of intellectual 
capacity and disorientation, and the inability to perform 
activities of daily living, such as dressing self, 
bathing, and personal hygiene (Sloan, 1998).
Behavioral manifestations of dementia include 
disturbance in sleep and appetite, agitation, psychotic
4
symptoms, apathy, as well as depressive and anxious 
features (Tariot, Schneider, & Porsteinson, 1997). These 
manifestations may persist for years and eventually may 
require a long-term health care approach. Patients are 
usually placed in nursing homes when caregivers can no 
longer care for them at home. The pharmacomedical economic 
cost for Alzheimer's disease has been estimated at $100 
million annually (Callaway, 1998).
There has been a 12% increase in the number of 
persons over the age of 65 years since 1900. Furthermore, 
the incidence of Alzheimer's disease is found in 20% to 
40% of persons over the age of 80 years. Obviously, the 
"graying of America" (Gambert, 1997) has had a notable 
impact on age-prevalent disorders; therefore, Alzheimer's 
disease has had a profound effect on the perception of the 
public and the medical community about mental illness in 
elders. Issues, such as wandering, confusion, agitation, 
incontinence, falls, and sleep disorders, present health 
care workers and families with difficult problems to 
treat.
Many long-term care residents have varying degrees of 
behavioral, social, emotional, and mental disorders and 
receive psychotropic drug therapy. Yet, frequently used as 
a realistic treatment for behavioral problems in the
5
Alzheimer's disease patient, psychotropic drug therapy has 
led to patients being overmedicated, declining cognitive 
status and memory, and an increase in the incidence of 
falls (Sherman, 1994).
Falls comprise the leading cause of fatal and 
nonfatal injuries in persons over 75 years of age. Long­
term psychotropic medication use has been strongly 
associated with the risk of falls in nursing homes. 
Research has revealed that elderly patients receiving 
psychotropic medications may be two to three times more 
likely to experience a fractured hip as opposed to those 
who did not receive psychotropic medications (Sherman,
1994).
In 1996 more than 250,000 older Americans suffered 
fractured hips at a cost in excess of $10 billion. More 
than 90% of hip fractures are associated with falls, and 
most of these falls occur in persons over the age of 70 
years. Elderly persons who fall are 10 times more likely 
to be hospitalized and eight times more likely to die as 
the result of a fall. Increased risk factors for falls in 
the elderly include the use of psychotropic medications, 
cognitive impairment, and sensory deficits (Fuller, 2000). 
Institutionalized elders have increased risk of serious 
complications associated with falls, such as pneumonia.
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skin breakdown, and deep venous thrombosis (Yeager et al.,
1995) .
Tardive dyskinesia is a condition characterized by 
involuntary facial movements, such as tongue protrusions 
and grimacing. At lest 40% of elders receiving 
psychotropic medications will develop some form of tardive 
dyskinesia. Despite its persistent nature, tardive 
dyskinesia is often missed or mistaken as a normal part of 
the disease process (Sherman, 1994). Tardive dyskinesia 
may be irreversible and can interfere with eating and 
swallowing, which causes weight loss and malnutrition and 
can ultimately lead to death (Yeager et al., 1995). 
Although tardive dyskinesia is persistent in nature, it 
can be mistaken for worsening of the disease process. This 
reaction frequently leads to an increase in the 
psychotropic medication dose being prescribed.
Significance to Nursing
The current researcher sought to describe the 
behaviors of the Alzheimer's disease patients before and 
after the institution of psychotropic medications.
Findings from this study may contribute to nursing 
research, theory, practice, and education.
Nursing research. This study contributed to the body 
of nursing research by providing new insights into
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understanding the behaviors of the Alzheimer's disease 
patient through documentation and comparison. Conduction 
of the study was important in identifying behavioral 
symptoms of Alzheimer's disease patients and the 
relationship between those symptoms and the medications 
used to control them. Data from this study provided 
relevant information for future health care professionals 
caring for Alzheimer's disease patients. Increasing 
awareness of the type of medications used underscores the 
importance of issues such as safety and improving quality 
of life for those with Alzheimer's disease. Finally, this 
research serves as a springboard from which to develop 
more studies focusing on the behaviors of the Alzheimer's 
disease patient and the medications used to treat them.
Nursing theory. This study served to advance 
Johnson's Behavioral System Model.as an appropriate basis 
for describing the behaviors of the Alzheimer's disease 
patient. Johnson's concepts of behavioral systems, 
equilibrium, stressors, and tensions are particularly 
relevant to the behavior of the Alzheimer's disease 
patient receiving psychotropic medication therapy.
Nursing practice. Findings from this study may be of 
significance to nurses and nurse practitioners charged 
with caring for persons with Alzheimer's disease. The
8
researcher sought to enable health care workers to 
understand the patient, behaviors exhibited, and the 
medications used in treatment of the behaviors. Patients 
with Alzheimer's disease receiving psychotropic 
medications require special attention due to the potential 
for declining cognition, memory deterioration, and 
physical limitations and the adverse effects associated 
with these variables. The informed health care 
professional has the opportunity to provide holistic care 
to Alzheimer's disease patients in the long-term care 
facility through increased understanding of the disease 
process and the medications used to control the symptoms.
Nursing education. As the elderly population 
increases and long-term care facilities become more 
prevalent, the need for long-term care professionals also 
will increase. Caregivers should be educated regarding the 
unique needs of the Alzheimer's disease patient and the 
medications used to treat dysfunctional behaviors. Nursing 
educational systems at both the baccalaureate and masters 
levels must continue to stay on the cutting edge of 
research and practice as the number of Alzheimer's disease 
clients in the health care delivery system continues to 
increase. Findings from this study may contribute valuable 
information to such programs.
Theoretical Framework
The theoretical framework guiding this study was 
Johnson's Behavioral Systems Model (Johnson, 1968). 
Johnson's model has been used in a variety of studies that 
support man as a behavioral system. In the current study 
the Alzheimer's disease patient's behavioral system was 
altered by both the disease and psychotropic medications.
Johnson developed the systems framework to provide 
direction for nursing theory, practice, education, and 
research. The goal of Johnson's theory was to maintain and 
restore balance in the patient by helping him or her 
achieve an optimal functional level. The major concepts of 
Johnson's model used in this study were behavioral system, 
equilibrium, tension, and stressor (Johnson, 1968) .
A behavioral system is a patterned, continual, and 
intentional way of behaving. This behavior forms an 
organized functional unit that provides interaction 
between the person and his or her environment. The 
patterned and repetitive ways of behaving that 
characterize man can be conceptualized as interrelated and 
interdependent parts that make up the whole person. This 
behavioral system is determined and controlled by 
biological, psychological, and social factors. Certain 
conditions must be met in order for the system to grow and
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survive. Problems manifested by disorganized or erratic 
behaviors represent disorders of the behavioral system. 
This conceptualization represents man as a behavioral 
system and disease as a biological system disorder 
(Johnson, 1968). The behavioral system of the Alzheimer's 
disease patient may be based on the ability to interrupt 
information and be affected by the environment.
Equilibrium is defined as a secure, but more or less 
temporary, resting state in which the individual is in 
accord with himself or herself and his or her environment. 
Equilibrium is not synonymous with a state of health since 
it may be found either in health or illness (Johnson,
1968) . Factors that may alter equilibrium for the 
Alzheimer's disease patient include the onset of 
confusion, loss of cognitive function, and memory. 
Medications used to treat these problems may also alter 
equilibrium and lead to loss of adaptation of the 
behavioral system.
Stressors refer to internal and external stimuli that 
produce tension and result in a degree of stability. 
Johnson (1998) states that stress is a process in which 
there is interaction between various stimuli and the 
defenses constructed against them. An unusual amount of
11
energy is required for the system to reestablish 
equilibrium in the aspect of stressful forces.
Tension is the state of being distended or forced and 
can be perceived as a disturbance in equilibrium. Tension 
can be destructive ineffective use of energy, hindering 
adaptation and causing potential structural impairment.
The stressors of the Alzheimer's disease patient usually 
occur from outside stimuli. Inability to adequately 
perform activities of daily living and memory loss provoke 
stress and tension which leads to agitation and 
frustration. The patient may be placed on medication to 
control behaviors that result from stressors which 
ultimately produce tension.
Johnson (1968) outlined health as an intangible, 
energetic state influenced by biological, psychological, 
and social factors. An individual attempts to achieve a 
balance in this system which will lead to functional 
behavior. A lack of balance in the structural or 
functional systems lead to poor health.
As the Alzheimer's disease patient in equilibrium 
attempts to achieve balance in the system, the behaviors 
exhibited affect the behavioral system. The psychotropic 
medications used to control the patient's behavior
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produces stressors that may alter the functional level of 
the system and produce tension (Gardner & Garrett, 1997).
In summary, Johnson's Behavioral Systems Model was 
chosen as the theoretical framework to guide this study 
because the concept of behavioral system and the 
subconcepts of equilibrium, stressors, and tension were 
particularly relevant to the issue of using psychotropic 
medications in elders with Alzheimer's disease. The 
current researcher sought to examine the behaviors of 
Alzheimer's disease clients before and after the 
implementation of psychotropic drugs in order to assess 
whether such drugs indeed help to maintain and restore 
balance by helping the patient achieve his or her maximum 
functional level.
Assumptions
The assumptions of this study were as follows:
1. Institutionalized Alzheimer's patients exhibit 
behaviors that can be measured.
2. Institutionalized Alzheimer's patients are 
receiving psychotropic medications to control their 
behavior.
3. Charting of behaviors and medication use is 
complete.
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4. Behavior is an ever-changing dynamic process 
(Johnson, 1968).
Statement of the Problem
The number of institutionalized persons with 
Alzheimer's disease is increasing as a result of the rise 
in the geriatric population. The behaviors exhibited by 
the Alzheimer's disease patient present the health care 
professional with a variety of concerns. The treatment of 
behavioral symptoms of patients has been controversial. 
Previous studies have shown that psychotropic medications 
may give rise to a worsening in cognitive decline and 
intensify adverse behaviors. Therefore, the problem of 
this descriptive comparative research was to examine the 
behaviors of the institutionalized patient with 
Alzheimer's disease and to determine whether these 
behaviors changed after the implementation of a 
pharmacologic regimen of psychotropic drugs.
Hypothesis
One null hypothesis guided this study: There will be 
no significant difference in the behaviors of 
institutionalized Alzheimer's disease patients before and 
after receiving psychotropic medication therapy.
14
Definition of Terms
For the purposes of this study, the following terms 
were defined theoretically and operationally:
1. Behaviors : the manner in which one acts ; the 
actions or reactions of individuals under specific 
circumstances (Thomas, 1993). Operationally, behaviors 
include conduct such as wandering, verbal abuse, physical 
abuse, socially inappropriate actions, screaming, hoarding 
items, and resisting care.
2. Alzheimer's disease patients: persons with 
progressive irreversible loss of memory, deterioration of 
intellectual functions, apathy, speech, and gait 
disturbance (Thomas, 1993). Operationally, Alzheimer's 
disease patients were all males and females at least 60 
years of age in the chosen institution at varying stages 
of Alzheimer's disease who had received at least one 
psycotropic medication.
3. Psychotropic medication therapy: medications 
classified according to the Physician's Desk Reference 
(AstraZeneca, 2000) as antidepressants, antipsychotics, 
sedative/ hypnotic, and antianxiety agents that affect 
psychic function, behavior, or experience (Thomas, 1993). 
Operationally, psychotropic medications classified as 
anxiolytics, antidepressants, hypnotics, and antipsychotic
15
prescribed for the patient population in the designated 
institution,
Summary
The focus of the study was to identify behaviors of 
the institutionalized Alzheimer's disease patient before 
and after receiving psychotropic medication therapy. In 
Chapter I the problem was introduced and the significance 
to nursing was described as well as the theoretical 
framework identified. One null hypothesis guided the 
researcher in assessing whether a difference in 
Alzheimer's disease patients' behaviors was appreciated.
Chapter II 
Review of the Literature
In a selected review of the literature, several 
studies were found related to Alzheimer's disease patients 
in nursing homes. However, studies specifically linking 
the role of psychotropic drugs to cognitive decline in 
Alzheimer's disease patients were limited.
Castle (1999) sought to identify resident and 
facility risk factors from the use of psychotropic drugs 
since the implementation of the Nursing Home Reform Act 
(NHRA) of 1987. The facility risk factors included 
facility size, Medicaid admissions, and patient census 
while resident risk factors included age, agitation, 
gender, and cognitive decline. Castle further sought to 
compare the findings with resident and facility risk 
factors of psychotropic drug use prior to the 
implementation of the NHRA.
Castle (1999) defined psychotropic drugs as those 
that affect psychic function, behavior, or experience and 
included the following four classes: antianxiety, 
antidepressant, sedative/hypnotic, and antipsychotic. The
16
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purpose of Castle's (1999) study was to determine the 
relationships between nursing home size, reimbursement 
class census, demographic area, clinical type, and 
corporate setting and the use of psychotropic drugs. A 
total of 268 facilities participated in the study. In each 
facility, depending on size, a fixed target sample of 8,
12, or 16 residents was selected, for a final sample of 
4,258. Two multivariate logistic regression models were 
used to predict psychotropic drug administration. Subjects 
were studied pre-NHRA (n = 2,170) and post-NHRA (n = 
2,088). The researcher used resident interviews, staff 
interviews, and review of the resident record, 
specifically the Minimum Data Set (MDS) assessment tool, 
to gather data. A multistage cluster sampling was used to 
analyze the data. The result was a more precise comparison 
of the differences between the groups being researched.
Castle (1999) found that before the institution of 
NHRA guidelines, physical impairments, increased age, and 
prior stroke were significantly less likely to be 
associated with antipsychotic drug use. Increased 
cognitive impairment, dementia, depression, and a history 
of psychiatric problems considerably increased the use of 
psychotropic drug administration. The researcher also 
found a nursing home being part of a chain of nursing
18
homes was associated with a lower.use of psychotropic 
agents (Castle, 1999) .
In 1993, post-NHRA increased physical and cognitive 
impairments, being female and having dementia, depression, 
and anxiety disorders increased the likelihood of 
psychotropic drug administration. Facilities with high 
occupancy of Medicaid patients were 13.8 times more likely 
to give antipsychotic medications, while overall a higher 
number of beds in the facility significantly decreased the 
administration of antipsychotics. Residents with anxiety 
disorders were more likely to receive antianxiety 
medication than other residents. The criteria for 
prescribing psychotropic medications became more rigid in 
1993, requiring more symptoms and behaviors. A major 
finding was that a history of psychiatric problems was 
still a significant reason for using antipsychotic 
medications.
Findings from the Castle (1999) study support the 
current research in view of the fact that the Nursing Home 
Reform Act of 1987 did initiate more stringent guidelines 
for psychotropic medication use in the nursing home 
setting. Despite the NHRA, psychotropic medications 
continue to be used to control behaviors of Alzheimer's 
disease patients regardless of nursing home size or
19
reimbursement status. Therefore, it is important for 
health care providers in long-term care settings continue 
to empirically assess whether such interventions 
significantly impact residents' behaviors, safety, and 
well-being.
Berg and Dellagega (1996) sought to explore the 
immediate and long-term consequences of psychoactive drug 
use on specific measures of intelligence and memory as 
indicators of overall cognitive ability. The researchers 
believed that negative effects occurred with use of the 
long-term use of psychoactive drugs among the elderly, 
both in the community and in the nursing homes, 
specifically in cognitive functional ability. The World 
Health Organization classification system was used to 
identify psychotropic medications as neuroleptic, 
antidepressants, anxiolytics, and sedative/hypnotic.
This longitudinal study included subjects taken from 
gerontological and geriatric populations. The studies were 
based on random samples drawn from the population in 
Gotenberg, Sweden. An original sample of 743 persons aged 
70 years was used. The continuing sample was followed up 
at three time periods : aged 70, 75, and 79 years.
Investigative procedures consisted of a two-part 
interview at each age period. The interview was conducted
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by a registered nurse who administered a battery of 150 
questions on health, social networks, the use of health 
care givers, and medications. Instrumentation included 
tests on mental ability and memory and intelligence. The 
memory test included the following: synonyms measuring 
verbal ability, block design measuring spatial ability, 
identical forms measuring perception, and memory measuring 
picture recognition. Intelligence was evaluated by fluid 
and crystallized knowledge and attention.
Two different approaches were used for data analysis. 
One was cross-sectional using the total groups at age 70, 
75, and 79 years, and the other was a repeated measures 
longitudinal design using only those still alive at age 79 
years and with valid scores at all three measurement 
points. The results of this analysis revealed that by age 
75 the use of psychotropic medications increased to 39% 
from 29% at age 70. By age 79 the overall rate dropped to 
36%.
Chi-square analysis revealed significant differences 
in the use of psychotropic medications based on gender at 
all three points of measurement. Women received more 
psychotropic medications than men.
To examine the relationship between the use of 
psychotropic medications and cognition, a separate
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cross-sectional analysis of performance scores was used, 
student's ;t tests were used to compare cognitive function 
between users and nonusers. Berg and Dellagega (1996) 
determined that elders at age 70 years who used 
psychotropic medications had significantly lower mean 
scores on the tests of verbal ability, spatial ability, 
and picture recognition and at age 75 lower scores on 
verbal ability, perception speed, and digit span. In the 
7 9-year-old group, all cognitive tests regressed backward 
and picture recognition was significantly lower for those 
subjects using psychotropic medications.
Berg and Dellagega (1996) concluded that as subjects 
aged they received increasing numbers of psychotropic 
medications. The highest rate of use was at age 75 years, 
and women received significantly more psychotropics than 
men. Berg and Dellagega (1996) also found a marked t rend 
toward stable functioning in subjects until these 
medications were introduced at which point a drop in 
cognition occurred. However, there was no indication that 
psychotropic medications improved cognitive function for 
any of the subjects at any time during the study. This 
study is germane to the current study in that the 
Alzheimer's disease patient's cognitive loss is
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inevitable; however, the rate of decline may depend on 
many factors including psychotropic medication use.
McShane and Keene (1997) sought to analyze the 
relationship between neuroleptic drugs and cognitive 
decline in dementia. The researchers also investigated the 
absence or presence of Lewy bodies in brain tissue 
postmortem of the cognitively impaired patient receiving 
neuroleptics. Cross-sectional surveys have shown that 
demented patients receiving neuroleptics have more 
cognition problems than those who do not ; however, 
neuroleptics are prescribed more often for behavioral 
problems. Side effects of neuroleptics include the 
worsening of behavioral disturbance of patients with 
dementia, increased falls, and fractures.
The hypothesis proposed by McShane and Keene (1997) 
that neuroleptics contribute to cognitive decline in 
people with dementia and decline in cognitive function is 
more rapid in patients treated with psychotropic 
medications who have cortical Lewy bodies postmortem. 
Cognitive decline was defined as increased physical 
aggression, disturbed diurnal rhythms, persecutory ideas, 
and hallucinations. Neuroleptic drugs were those drugs 
used to treat behavioral complications of dementia and 
included thioridazine, promazine, haloperidol, and
23
chlorpromazine. Lewy body refers to increased 
neuropathological substances typical in brain tissue of 
Alzheimer's disease patients.
McShane and Keene's (1997) 2-year longitudinal study 
consisted of interviews every 4 months, with autopsy 
performed on those who died during the study. The 
dependent variable for the study was the rate of cognitive 
decline. The independent variables were sex, duration of 
dementia, and cognitive score at study entry. Seventy-one 
subjects with dementia were recruited through general 
practitioners and psychiatric nurses. Most subjects had a 
diagnosis of Alzheimer's disease at autopsy. The mean age 
at entry was 72 years, and 37 of the subjects were men.
The age of onset of dementia was less than 65 years in 11 
patients, and the mean duration of dementia was 5.7 years.
McShane and Keen (1997) utilized the Minimental State 
Examination (MMSE) to measure cognitive function scores. A 
multiple regression analysis was performed on the 
subjects' scores on the MMSE. Age, sex, duration of 
dementia, and cognitive score at study entry were entered. 
Neuroleptic use and mean scores over six interviews for 
hallucinations, persecutory ideas, physical aggression, 
and disturbance of diurnal rhythms were entered stepwise.
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A second analysis consisted of autopsy of 42 patients 
indicating the presence or absence of cortical Lewy 
bodies. Cortical Lewy body pathology did not make an 
independent predictor of cognitive decline.
The decline in the mean score for the expanded 
examination in the patients who took neuroleptics was 
twice those patients who did not take neuroleptics. An 
increased rate of decline was also associated with 
aggression, disturbance of diurnal rhythm, persecutory 
ideas, and hallucinations. There was no correlation 
between the rate of cognitive decline and the dose of 
neuroleptic drug therapy.
A third analysis was performed to determine a 
temporal relationship between the use of neuroleptics on 
20 experimental subjects who had taken neuroleptics for at 
least 4 months. The decline in the mean score for the 
expanded examination in the patients who had taken 
neuroleptics was twice that of patients who did not take 
neuroleptics.
McShane and Keene (1997) determined that the use of 
neuroleptics causes and increases in the rate of cognitive 
decline. This association was dependent on the degree of 
dementia and behavioral symptoms for which the neuroleptic 
drug might have been used. The findings also revealed that
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the point when patients started treatment coincided with 
an increase in the rate of cognitive decline. The 
researchers also revealed that neuroleptics used to treat 
behavioral complications of dementia might worsen already 
poor cognitive abilities. The McShane and Keene (1997) 
study is relevant to the current research because 
identification of the relationship between neuroleptic 
medications and cognitive decline provides more scientific 
information about the progression of Alzheimer's disease 
and its associated behaviors.
Jacobson and Winograd (1994) sought to analyze the 
differing perspectives among physicians, nursing staff, 
and patients about psychoactive substance use in the long­
term care setting. The researchers noted that nighttime 
disorders including both insomnia.and behavior problems 
had a reported incidence of 45% to 64% among 
institutionalized elders. Psychotropic medications were 
used to manage these symptoms with a reported frequency of 
53% to 65%. The researchers have questioned the 
effectiveness, appropriateness, and risk/benefit of these 
medications.
The psychotropic medications identified by Jacobson 
and Winograd (1994) were antipsychotics, anxiolytics, 
antidepressants, and sedative/hypnotic. The antipsychotic
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drugs used were haloperidol, thioridazine, and 
trifluperazine. The anxiolytics included only Ativan while 
the antidepressants included amitriptyline, despramine, 
nortriptyline, and trazadone. Under the sedative/hypnotic 
category were chloral hydrate, diphenhydramine, 
flurazepam, temazepam, and triazolam.
Jacobson and Winograd (1994) defined nighttime 
behavioral symptoms as agitation, restlessness, 
combativeness, wandering, and yelling. Insomnia was 
operationally defined as frequent awakenings, increased 
sleep induction, and short sleep duration.
Research subjects included 58 residents in a skilled 
nursing facility. Of the 58 residents, 38 were receiving 
no psychotropic medications, 5 had pro re nata (PRN) 
orders for psychotropic medications but were not receiving 
any and 15 (26%) were receiving psychotropic medications
on a regular basis. Consent was obtained from 14 of the 15 
residents receiving psychotropic medications. Three 
residents were receiving psychotropic drugs on a PRN basis 
at least five to six times a week.and were included in the 
study. To determine which patients could provide reliable 
data, the Folstein's MiniMental Status Examination (MMSE) 
was used. Of the residents who met other inclusion
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criteria, only 6 could complete the interview with MMSE 
scores > 15.
Data were collected from the three following groups 
of subjects: (a) the patients themselves, (b) 14 members
of the nursing staff, and (c) the patients' personal 
physicians. Instrumentation involved the use of a 
questionnaire interview. The interview addressed four 
domains related to nighttime disorders : (a) description,
(b) presumed etiology, (c) management, and (d) impact of 
nighttime disorder, including side effects of medications. 
The Description domain addressed the presence of insomnia 
and nighttime behavior problems. The Etiology domain 
addressed the presumed source of the problem. The 
Management domain investigated the perceived efficacy of 
the medications and the presence of alternate coping 
strategies. The Impact domain explored physical, 
psychological, and social effects of the disorder and the 
medication.
The nurse's interview included only those domains 
appropriate to their interactions with the patients. The 
patients responded to objective verifiable questions, and 
their responses were included in the study. The 
physician's interview consisted of fewer questions to 
maximize participation; however, the physician
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questionnaire was similar enough to the patients and staff 
to ensure valid comparison.
In comparing the responses of the three groups, the 
researchers noted differences when two of the groups 
disagreed on the presence of a condition or a problem. To 
calculate the percentage of different responses for each 
category, the number of the responses was divided by the 
two groups which had disagreed (i.e.. Group 1, yes; Group 
2, no; and Group 1, no/Group 2, yes) by the total number 
of responses.
Jacobson and Winograd (1994) found a high frequency 
of disagreements, ranging from 47% to 63% among patients, 
staff, and physicians. The respondents differed in 
identifying the presence of nighttime disorders and in 
assessing the efficacy and impact of psychotropic 
medications on the patient's daily life. Patients and 
nursing staff had differing opinions 67% of the time. The 
nurses reported physical problems, such as pain, dyspnea, 
and frequent urination, as the cause for insomnia twice as 
often as the patients. The nurses and patients differed 
33% of the time regarding medication efficacy. In managing 
their nighttime disorders the patients reported coping 
methods, such as relaxing, reading, remembering family 
members, and prayer. The nursing staff did not recognize
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any of these coping methods. On questions addressing 
psychological effects, including fatigue, patients and 
nurses disagreed 50% of the time. The patients denied 
confusion while the nurses reported that confusion 
occurred frequently.
The patients and the physicians disagreed on the 
effectiveness of the medication 67% of the time, with the 
physicians believing the medication was effective three 
times more often than the patients. While the physician 
believed there were few adverse effects, four out of six 
patients felt there were adverse effects from psychotropic 
medication. The physicians believed that 10 out of 14 
patients responded well to the medication and that 70% of 
these patients continued to experience significant 
nighttime disturbances according to the medical record.
The physicians and the nursing staff disagreed about 
the presence of insomnia 43% of the time. The nurses 
thought the disorder existed twice as often as the 
physicians. They also disagreed on the effectiveness of 
the medication 50% of the time, with the physicians 
stating that the medication was effective more often. The 
two groups disagreed 7 9% of the time on the impact of the 
medications on the patient's daily life. The nurses 
identified problems for 11 out of 14 patients, while the
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physicians reported none. Differences in the responses 
regarding the medications' efficacy and impact raised 
questions of appropriateness of psychotropic drug use 
among the elders. The nursing staff believed the 
medication was effective for only 64% of the patients.
Yet, even for these patients, the nursing staff records 
indicated that they continued to experience nighttime 
disorders.
This study had two major limitations. First, Jacobson 
and Winograd (1994) did not operationally define 
agitation, restlessness, and anxiety. Instead, the 
conditions and disorders were described in the manner used 
clinically by the staff. A second limitation was the small 
number of patients who completed the interview, since only 
6 of the 14 patients could complete the interview with 
some degree of reliability.
Findings from the Jacobson and Winograd (1994) study 
suggest that patients, nursing staff, and physicians 
perceive nighttime disorders and their management 
differently and improved methods of communication and 
education are needed. Despite these findings, nursing home 
patients with nighttime disorders are often managed with 
psychotropic medications. The current researcher found the 
Jacobson and Winograd (1994) study helpful because it
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increased awareness of the differing perceptions among 
patients, staff, and physicians regarding the use of 
psychotropic medications and control of behavioral 
symptoms. The nursing staff indicated increased confusion 
and nighttime disorders associated with psychotropic drug 
use. The current researcher also sought to identify 
behaviors documented by the nursing staff before and after 
the institution of psychotropic drug use in elders.
The major source of problems for physicians treating 
Alzheimer's disease is controlling the psychotic types of 
symptoms experienced by the persons affected. A primary 
predictor of cognitive and functional decline in 
Alzheimer's disease is a worsening of psychotic symptoms, 
such as delusions, hallucinations, aggression, and 
psychomotor function (Lopez, Wisniewski, Becker, Boiler, & 
DeKosky (1999). Although the literature seems to support 
the position that psychosis and abnormal behavior can 
affect the progression of Alzheimer's disease, few studies 
have taken into account the medications used.
Lopez et al. (1999) examined whether the use of 
psychiatric medication and the presence of abnormal 
behaviors affects the progression of Alzheimer's disease.
A cross-sectional design was used with longitudinal 
follow-up and the likelihood of arriving at one of four
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points: (a) MiniMental State exam (MMSE) score of 9 or
lower, which examines cognitive and mental status; (b) 
Blessed Dementia Rating Scale (BDRS) score of 15 or less, 
which measures ability to perform activities of daily 
living; (c) nursing home admission; and (d) death.
Psychiatric medication included antidepressants, 
antipsychotic agents, and sedative/hypnotics. The 
psychotic symptoms described include such symptoms as 
delusions, hallucinations, aggressive behavior, 
psychomotor agitation, wandering, and depression.
The setting was the Multidisciplinary Dementia 
Research Clinic in Pittsburgh, Pennsylvania. The subjects 
consisted of 17 9 mildly to moderately impaired patients 
with probable Alzheimer's disease. Patients were observed 
from 2.4 to 172 months (mean duration + SD, 49.5 + 27.4 
months). Each patient received an extensive neurological, 
psychiatric, and neuropsychological examination prior to 
the study. Patients with clinical or radiological evidence 
of cerebrovascular disease were not included in the study.
Subjects were examined annually, and the follow-up 
period ranged from 0.2 to 14.6 years (mean follow-up 
period + SD, 4.16 + 2.38 years). Psychiatric evaluations 
were conducted annually by psychiatrists using a
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semistructured interview with patients and primary 
caregivers.
The medications used by the patients were recorded on 
a summary form that included dosages, date of the initial 
prescription, and date of discontinuation of medication. 
The referring physician conducted the selection, 
administration, and response evaluation of each treatment.
Student ;t tests were used to analyze demographic and 
neuropsychiatrie data. Proportional hazard models were 
used to determine if there were differences in the time 
from study entry to death, institutionalization, BDRS 
scores of 15 or higher, and MMSE scores of 9 or lower 
between patients with Alzheimer's disease with and without 
psychiatric symptoms and as a function of medication use 
and type. Proportional hazard models were also used to 
individually assess the effect of the presence of 
individual symptoms or medication-induced symptoms on 
these same outcomes. The effects of individual symptoms 
and medications were assessed as time-dependent 
covariates.
A step-wise selection procedure was used to determine 
which psychiatric symptom or medication was independently 
associated with the outcome measures, after adjusting for 
possible confounding variables, such as sex, age, and
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educational background. For patients not reaching an 
outcome (e.g., death, institutionalization, BDRS score of 
> 15, MMSR score of < 9), data were censored using the 
date of the last contact.
A total of 41 patients (23%) were taking at least one 
psychiatric medication at study entry; 22 (12%) took
antidepressants, 16 (9%) took antipsychotic agents, and 11 
(6%) took sedative/hypnotics. The relationship between the 
medication and the symptoms indicated that 18% of the 
patients had verbal or physical aggression, 23% had 
psychomotor agitation, 7% experienced wandering, 29% 
suffered from insomnia, 13% had major depression, and 26% 
experienced psychotic symptoms at baseline examination.
During follow-up, 18% of the patients were noted to 
be aggressive, 38.5% experienced psychomotor agitation,
19% wandering, 37% insomnia, 9% depression, and 38% 
psychosis. There were more patients treated than not 
treated who had aggression (p < .001), psychomotor 
agitation (p < .001), and depression (p < .001). At 
baseline examination, 17% of the 41 treated patients were 
taking two or more drugs, 7% were treated with 
antidepressants and antipsychotic agents, 7% with 
sedative/hypnotics and antidepressants, and 5% with three 
types of medication. During follow-up 43% took psychiatric
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medications, 12% took antidepressants, 22% antipsychotics, 
and 13% sedative/hypnotics, 15% were treated with more
than one psychiatric medication, 3% with antidepressants 
and sedative/hypnotic agents, 4% with antidepressants and 
antipsychotics, 8% with antipsychotic and 
sedative/hypnotics, 4% used more than one antipsychotic
agent, 1% used more than one antidepressant, and 1% used 
more than one sedative/hypnotic agent.
Seventy-four (41%) of the 179 patients were 
institutionalized, 101 (56%) died, 55 (31%) reached BDRS
score of 15 or higher, and 76 (42%) reached and MMSE score 
of 9 or lower. Cox proportional hazard models were used to 
examine the univariate effect of medication and individual 
psychiatric symptoms on the outcome variables. Of the 
psychiatric medications, antipsychotic agents were 
associated with time to BDRS scores of higher than 15 (RR 
= 2.02, p = .03) and with institutionalization ( ^  = 2.14, 
p = .02), sedative/hypnotics were associated with time to 
death (R^ = 1.96, p = .05).
Psychosis, aggression, and agitation were all 
independently associated with time to 
institutionalization. Antipsychotic agent use was 
associated with BDRS scores of 15 or higher and use of 
sedative/hypnotics with time to death.
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The number of patients with psychomotor agitation, 
insomnia, psychosis, and wandering increased during the 
follow-up, while the number with depression and aggressive 
behavior decreased. Psychotic symptoms were significant 
predictors of institutionalization and functional decline, 
but not of death.
Lopez et al. (1999) determined that one of the 
problems in the treatment of Alzheimer's disease is the 
lack of agreement regarding who should be treated and 
noted most of the patients with behavioral problems were 
not being treated at study entry, except those with 
depression. As the disease progressed, more patients began 
treatment, especially those with agitation or aggression. 
Of the patients with psychotic symptoms, less than one 
half received any medication.
A second implication of the Lopez et al. (1999) study 
was the need to more closely examine what types of 
psychotropic medications should be used for what types of 
symptoms. Antidepressants were not only used to treat 
depression but also insomnia and episodes of nocturnal 
agitation. In the study antipsychotic agents and sedatives 
were used to treat agitation, wandering, aggression, and 
insomnia. This finding suggests that the choice of 
treatment may be guided by the most disturbing symptom.
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The current researcher also was interested in the use of 
psychotropic medications used to treat Alzheimer's disease 
and the progression of the disease process. The focus of 
the current research was to identify behaviors before and 
after beginning psychotropic medication therapy.
Although there were few studies available, the review 
of the literature provided valuable information regarding 
Alzheimer's disease progression, behaviors, cognitive 
decline, and medications used to treat the symptoms. This 
study will serve to augment the limited research available 
regarding the use of psychotropic medications in 
Alzheimer's disease.
Summary
In this review of the literature, the studies cited 
have shown that psychotropic medications do affect 
cognition and memory of Alzheimer's disease patients. 
Castle (1999) examined nursing home size and funding 
status and found that nursing homes with a high Medicaid 
census used more psychotropic medications. In Berg and 
Dellagega's (1996) study the long-term use of 
psychotropics was explored. Berg and Dellagega determined 
that elders who used psychotropic drugs had lower 
cognition scores overall. The researchers further 
concluded that as the subjects aged, more psychotropic
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medications were prescribed. McShane and Keene (1997) 
found that the use of psychotropic medications appears to 
increase the rate of cognitive decline in elders. Jacobson 
and Winograd (1994) found differing opinions from nurses, 
physicians, and patients regarding the use of psychotropic 
medications and their effects.
Numerous studies have been published regarding the 
use of psychotropic medications and dementia of all types; 
however, few address the behavioral problems experienced 
by the recipients of such drugs. The behaviors of the 
Alzheimer's disease patient are complex in that they exist 
with and without medications. Thus, the current researcher 
determined that additional studies were needed to 
determine the behaviors exhibited by the Alzheimer's 




The purpose of this study was to describe behaviors 
of institutionalized Alzheimer's disease patients before 
and after receiving psychotropic medication therapy. This 
chapter addresses the design of the study, including 
variables, research questions, and limitations. Also 
discussed in this chapter are setting, population and 
sample, methods of data collection, and data analysis.
Design of the Study
The researcher chose a descriptive comparative 
research design in order to identify behaviors of 
Alzheimer's disease patients receiving psychotropic 
medications. The researcher used the sign in order to 
describe the variables of interest without manipulating 
them or implying causation for why the variables exist as 
they do. The Behavioral Assessment for Institutionalized 
Alzheimer's Patients Tool was adapted from the MDS 2.0 
User's Manual (MDS) (1998) for nursing home patient 
assessment and was used to describe the behaviors of
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Alzheimer's disease patients before and after psychotropic 
medications were used.
Variables
The variables of interest for this study were the 
behaviors exhibited by Alzheimer's disease patients and 
the psychotropic medications used to treat them as 
measured by the Behavioral Assessment for 
Institutionalized Alzheimer's Patients. Intervening 
variables may have included the stage of disease clients 
were in when admitted to the nursing home and incongruence 
in the estimation of behaviors by the nurses as documented 
on the MDS (1998) for nursing home patient assessment.
Limitations
One limitation of the present study was the design 
since the researcher lacked control of the variables and 
the ability to manipulate the independent variable.
However, utilizing this design with a chart review was 
appropriate as it allowed the researcher to gain 
information about Alzheimer's disease behaviors as they 
were perceived by nurses in the patient's natural 
environment.
The research also was limited by the complexity of 
the cognitively impaired individual. In an effort to
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offset this limitation, the researcher adapted the 
Behavioral Assessment for Institutionalized Alzheimer's 
Patients from the Minimum Data Set (MDS) for nursing home 
patients' assessment. The MDS is the standard assessment 
tool for the institutionalized resident in the nursing 
home setting. Effort was made to operationally define the 
behaviors of the Alzheimer's disease patients according to 
the MDS and to specifically identify the psychotropic 
medications used during the time MDS assessments were 
documented.
Another noted limitation for this study was the long­
term care setting, which may not truly reflect behavioral 
symptoms of all Alzheimer's disease patients receiving 
psychotropic medications but was chosen for access to the 
population. External validity refers to the ability to 
generalize the findings to other settings or samples 
(Polit & Hungler, 1999). Because the sample was drawn from 
one nursing home in one part of the United States, 
findings may not be applicable to the larger population of 
institutionalized or homebound elders with Alzheimer's 
disease.
Setting, Population, and Sample
The setting for the study was a long-term care 
facility in a southeastern rural state. The facility was
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chosen because of its geographical proximity to the 
researcher. The population included patients in the long­
term care facilities with a diagnosis of Alzheimer's 
disease who were receiving psychotropic medication 
therapy. In order to increase validity of the study, only 
one psychotropic drug was included in the study. The 
target sample (N = 40) consisted of patients in the long­
term care facility. Participants were obtained through 
personal visits by the researcher to the long-term care 
facility who solicited help from the MDS nurse and the 
Director of Nursing.
Methods of Data Collection
Instrumentation. A researcher-designed Behavioral 
Assessment for Institutionalized Alzheimer's Patients (see 
Appendix A) was used to determine the behaviors exhibited 
by Alzheimer's disease patients before and after receiving 
psychotropic medications. This tool consisted of eight 
items, one to identify diagnosis, six to measure memory, 
cognitive skills, delirium-disordered thinking, indicators 
of depression, anxiety, and sad mood, change in mood, 
behavioral symptoms, and a final item to identify 
psychotropic medications received. Information gathered 
from each patient's chart was recorded directly on the 
tool. A panel of experts assessed face validity.
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A total of 6 scores by a rating scale were obtained 
from the Behavioral Assessment for Institutionalized 
Alzheimer's Patients. Mean scores were used to determine 
the behaviors of the subjects before and after 
psychotropic medication therapy.
Procedure. Permission was obtained to conduct the 
study from the Committee on Use of Human Subjects in 
Experimentation from Mississippi University for Women (see 
Appendix B). Permission was also obtained from the 
institution utilized in the study (see Appendix C). The 
MDS nurse and the Director of Nursing provided patient 
charts relevant to the study, which contained diagnosis of 
Alzheimer's disease and psychotropic medication use. The 
responsible party of each subject was contacted, and 
permission was granted to review each subject's chart (see 
Appendix D). Patient names or chart numbers were not 
included on the Behavioral Assessment for
Institutionalized Alzheimer's Patients in order to assure 
confidentiality. Information was recorded on the 
assessment for statistical analysis.
Method of Data Analysis
Statistical results were examined to identify the 
strength of relationship between the variables. Data were 
gathered and grouped by behaviors before and after
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psychotropic medication therapy. Results from the 
Behavioral Assessment for Institutionalized Alzheimer's 
Patients were analyzed using the t test. Analysis using 
the t test is commonly used in situations in which a 
single group yields pretreatment and post-treatment scores 
(Polit & Bungler, 1999).
Summary
Chapter III described empiricalization of this 
research study, which explored the behaviors of the 
Alzheimer's disease patients receiving psychotropic 
medication therapy. The design of the study, including 
variables, research questions, and limitations to the 
study were addressed. The setting, population, and sample 
of the study were discussed. Methods of data collection, 
including instrumentation and procedures, were also 
discussed. Finally, data analysis was explained.
Chapter IV 
The Findings
The purpose of this study was to identify the effects 
of psychotropic medications on the behaviors of the 
institutionalized Alzheimer's disease patient. A 
descriptive study was implemented to describe the 
behaviors exhibited by the Alzheimer's disease patient 
before and after receiving psychotropic medications. 
Empiricalization of the study is explained in this 
chapter. A description of the participants is presented, 
followed by outcomes of data analysis related to the 
research question.
Description of the Sample
The sample (N = 33) consisted of Alzheimer's disease 
patients in a long-term care setting receiving 
psychotropic medication therapy. Of the participants,
26.5% were male and 73.5% were female. Each participant 
had a diagnosis of Alzheimer's disease and received at 
least one psychotropic medication, with 29.4% receiving 
antidepressants, 32.4% receiving antipsychotics, 17.6%
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receiving sedative/hypnotics, and 20.6% receiving anxiolytics
The long-term care facility chosen for the study 
housed 125 residents. The sample (N = 33) was the total 
number of residents who met the criteria of diagnosis and 
medication. All of the participants had been in the 
facility for at least 6 months.
Results of Data Analysis
One hypothesis guided this study. The hypothesis was 
as follows: There will be no significant difference in the 
selected behaviors of institutionalized Alzheimer's 
disease patients before and after receiving psychotropic 
medication therapy. A t test was used to determine the 
significance of any difference in behavior for each 
selected behavior on the Behavioral Assessment for 
Institutionalized Alzheimer's Patients. The selected 
behaviors analyzed were memory/recall ability, cognitive 
skills, delirium-periodic disordered thinking, indicators 
of depression, anxiety and sad mood, and behavioral 
symptoms.
For memory there was a significant decline after 
taking psychotropic medications. The majority of the 
participants went from the ability to remember four or 
more items to remembering none. The items of memory and 
recall included recognition of current season, location of
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room, staff names and faces, and nursing home placement. 
These findings are presented in Table 1.
Table 1
Memory and Recall Behaviors of Alzheimer's Disease 
Patients Using a t Test
Memory/Recall M SD t p ’̂
No items recalled
Pretest 33 1.47 1. 002
2 . 45 . 02*
Posttest 33 1.03 1. 060
p < .05.
The cognitive skills for daily decision making ranged 
from independent decision making to severely impaired 
decision making. Independent decision making indicated 
that the participants made consistent and reasonable 
decisions. Modified independence indicated some difficulty 
in new situations while moderately impaired decision 
making required cues or supervision. Severely impaired 
decision making indicated that the participant rarely or 
never made decisions. The findings were significant in 
that there was an overall increase in cognitive function 
of the Alzheimer's disease patient after receiving
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psychotropic medications. These findings are presented in 
Table 2.
Table 2
Disease Patients Using a t Test
Cognitive













In the area of delirium-periodic disordered 
thinking/awareness, there was a significant increase in 
periods of restlessness, fidgeting, and repetitive 
physical movements of the Alzheimer's disease patients 
receiving psychotropic medications. The areas in which 
there was no decline included attention span, periods of 
altered perception or awareness of surroundings, episodes 
of disorganized speech, periods of lethargy, and varying 
mental function. There was, however, an increase in 
periods of restlessness which included fidgeting or 
picking at skin, clothing, napkins, etc., frequent
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position changes, repetitive physical movements, 
wandering, pacing, or calling out. These findings are 
presented in Table 3.
Table 3
Indicators of Delirium and Disordered Thinking/Awareness
of Alzheimer's Disease Patients Using a t Test
Indicator M SD t p*
Easily distracted
Pretest 33 . 471 .507
-.297 .768
Posttest 33 . 500 . 510
Periods of altered
perception
Pretest 33 . 320 . 470
-1.710 .096




Pretest 33 .260 .450
-1.000 .325
Posttest 33 .350 .490
Periods of
restlessness
Pretest 33 .260 . 450
-2.260 .030*




Indicator M SD t p*
Periods of
lethargy
Pretest 33 . 150 . 440
- .373 .711





Pretest 33 . 350 .490
-1.710 .096
Posttest 33 . 500 . 510
'p < . 05 .
For indicators of depression, anxiety, or sad mood 
there was a significant increase in unrealistic fears, 
such as fear of being left alone, abandoned, or being with 
others. There was also an increase in the behavior of 
repetitive questions, such as "where do I go" and "what do 
I do?" and crying and tearfulness of the Alzheimer's 
disease patient receiving psychotropic medications also 
escalated. There was no increase in the behaviors of 
negative statements and verbalizations such as calling 
"help." There were no indications.of an increase in anger 
with self and others, self-deprecation, or repetitive 
health complaints. The findings are presented in Table 4.
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Table 4
Indicators of Depression, Anxiety, and Sad Mood of 
Alzheimer's Disease Patients Using a t Test



























































Indicator M SD t p*
Unrealistic
fears
Pretest 33 -.294 . 170




Pretest 33 . 120 .330






Posttest 33 .410 .560
-2.23 .033*
*<.05.
For negative behavioral symptoms of the Alzheimer's
disease patient receiving psychotropic medications, the 
data analysis revealed that there was an increase in 
physically abusive behavior, such as hitting, shoving, 
scratching, and sexual abuse of others. There was no 
increase in the behaviors of wandering with no rational 
purpose, verbal abuse, such as threatening other 
residents, and socially disruptive behavior, such as 




Behavioral Symptoms of Alzheimer's Disease Patients Using
a t Test
Behavior
symptom df M SD t p*
Wandering
Pretest 33 .265 .567
-1.750 .088
Posttest 33 .500 .860
Verbal abuse
Pretest 33 .240 .430
-1.070 .292
Posttest 33 .350 .490
Physical abuse
Pretest 33 .180 .390
-2.260 .030*




Pretest 33 . 120 .330
-1.430 .160
Posttest 33 .240 . 430
*< .05.
Since there was a significant change in areas of all
behaviors assessed. the researcher rejected the null
hypothesis.
Summary
The results of the data analysis were described in 
Chapter IV. The sample including demographics were
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included. Each item of the Behavioral Assessment for 
Institutionalized Alzheimer's Patients was statistically 
analyzed to determine if any significance could be 
identified. Results from statistical analysis of 
Alzheimer's disease patients' behaviors and psychotropic 
medications showed a significant correlation. The 
initiation of psychotropic medications did adversely 
affect the behavior of the Alzheimer's disease patient. 
Chapter V will provide an outcome of the findings 




An explanation of the findings of this study in 
relation to the research problem is summarized and 
discussed in this chapter. Conclusions are drawn, 
implications for nursing are examined, and recommendations 
for nursing science are made.
Psychotropic medications are frequently used to treat 
the behavioral symptoms of the Alzheimer's disease 
patients in the long-term care setting. The use of 
psychotropic medications in the longer-term care setting 
has been presented in the literature; however, research 
relating to psychotropic medications and institutionalized 
Alzheimer's disease patients is limited. This descriptive 
study examined the use of psychotropic medications on the 
behaviors of institutionalized Alzheimer's disease 
patients. Data were collected using the researcher-adapted 
Behavioral Assessment for Institutionalized Alzheimer's 





A total of 33 Alzheimer's disease patients were 
studied with 26.5% male and 73.5% female. Psychotropic 
medications identified were antidepressants, 
antipsychotics, sedative/hypnotics, and anxiolytics. The 
null hypothesis that guided this study was as follows: 
There will be no significant difference in the behaviors 
of institutionalized Alzheimer's disease patients before 
and after receiving psychotropic medication therapy. The 
six categories measured were memory/recall ability, 
cognitive skills for daily decision making, indicators of 
delirium-periodic disordered thinking/awareness, 
indicators of depression, anxiety, sad mood, change in 
mood, and behavioral symptoms. The findings revealed a 
significant change in each of the six categories; 
therefore, the null hypothesis was rejected.
Discussion
Findings revealed that the memory/recall ability of 
the Alzheimer's disease patient declined after the 
introduction of psychotropic medications. The Behavioral 
Assessment for Institutionalized Alzheimer's Patients 
measured the number of items remembered. Current season, 
location of room, staff names or faces, and awareness of 
being in a nursing home were the elements of the
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memory/recall ability section. The study sought to reveal 
how many of these items were remembered or if none were 
remembered. The memory loss exhibited by the Alzheimer's 
disease patients receiving psychotropic medications could 
have been due to side effects from the drugs, such as 
apathy, anxiety, drowsiness, or confusion. Although the 
normal progression of Alzheimer's disease is a gradual 
worsening in memory, psychotropic drugs may potentiate 
memory loss due to the fact that the elderly do not 
metabolize drugs as effectively as younger people.
The cognitive skills for daily decision-making 
ability increased in the patients. The Behavioral 
Assessment for Institutionalized Alzheimer's Patients 
measured decisions regarding the tasks of daily life. 
Specific findings included the following:
1. Modified independence was identified as some 
difficulty in new situations only.
2. Moderate cognitive impairment required cues or 
supervision for adequate decision making.
3. Severe cognitive impairment was indicated by 
decisions being rarely or never made.
The finding of an increase in cognitive decision 
making in the light of worsening memory was surprising. 
This finding may be explained by the fact that although
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the memory may be worsened for the Alzheimer's disease 
patient with the use of psychotropic drugs there may be an 
increase in concentration. Even though the patient may not 
be aware of the season or nursing home placement, clothing 
may be selected or food likes or dislikes may be favored,
i.e., when asked, "Which pair of pants do you want to 
wear?" the patient may choose one. This would indicate an 
increase in cognition.
Berg and Dellagega (1996) and McShane and Keene 
(1997) seem to contradict the current research in the area 
of cognition. Berg and Dellagega explored factors that 
affected cognitive function of elders including 
psychotropic medications. The results of the study 
revealed that elders who used psychotropic medications had 
significantly lower cognitive scores than elders who did 
not use psychotropic medications. McShane and Keene found 
that demented patients receiving psychotropic medications 
had more cognition problems than those who were not 
receiving such drugs. Findings revealed that physical 
aggression, hallucinations, and persecutory ideas were 
present in these patients. The findings of the current 
research indicate an increase in cognitive function after 
receiving psychotropic medications.
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The indicators of delirium-periodic disordered 
thinking/awareness measured whether or not the behavior 
was present and appeared different from the residents' 
usual functioning. The following items are examples of the 
indicators that were measured:
1. Easily distracted indicated difficulty paying 
attention or easily sidetracked.
2. Periods of altered perception or awareness of 
surroundings as demonstrated by moving lips, talking to 
someone who is not present, belief that the patient is 
somewhere else, and confusion between night and day.
3. Episodes of disorganized speech were determined by 
fidgeting or picking at skin or clothing, frequent 
position changes, repetitive physical movements, 
wandering, pacing, or calling out.
4. Sluggishness, staring, difficult to arouse, and 
little body movements indicated periods of lethargy.
5. The changes in mental function of the Alzheimer's 
disease patient, such as deterioration in memory as the 
day goes on, indicated mental function varying over the 
course of the day.
The findings revealed that the episodes of delirium- 
periodic thinking/awareness were increased as indicated by 
an increase in periods of restlessness. The periods of
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restlessness may be explained by the fact that the 
increased cognition may have triggered restlessness in the 
patient receiving psychotropic medications because the 
patient may have been more cognizant to some facts as 
previously described. The increased restlessness may have 
also been psychotropic drug-induced anxiety. This finding 
is consistent with the findings of Lopez et al. (1999) 
which indicated that psychotropic medications cause an 
increase in psychomotor movements.
The episodes of depression, anxiety, and sad mood 
were measured from not occurring to occurring within the 
last 30 days or occurring 6 to 7 times a week. The 
behaviors that indicated depression, anxiety, and sad mood 
were as follows:
1. Statement such as "nothing matters," "would rather 
be dead," and "what's the use?"
2. Repetitive questions, such as "Where do I go?" and 
"What do I do?"
3. Calling out for help or other repetitive 
verbalizations.
4. Persistent anger with self or others from nursing 
home placement to anger at care received.
5. Self-deprecation statements of unworthiness.
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6. Expression of what appears to be unrealistic 
fears, fears of being abandoned, left alone, or of being 
with others.
7. Repetitive health complaints and obsessive concern 
with body functions.
8. Crying and tearfulness.
The findings indicate an increase in the area of 
unrealistic fear. These fears included fear of being 
abandoned, left alone, and also fear of being with others. 
Again, this may also be correlated to the increase in 
cognition because of an interest in awareness and thought 
but at the same time decrease in memory may provoke 
feelings of fear. The fear of being with others, such as 
health care professionals, may ignite fears of the unknown 
(i.e., procedures and medications) and the relation of the 
possibility of painful stimuli. The fear of being with 
others may also include family members. The patient may 
experience feeling of guilt, shame, or frustration which 
may appear as fear during times of family confrontation.
The last item measured was behavioral symptoms which 
included wandering, verbal abuse, physical abuse to staff 
or other residents, and socially inappropriate behavior 
such as disrobing in public. A range of the behavior not 
occurring in the last 7 days to the behavior occurring
62
daily were used to measure these areas. The findings 
revealed an increase in physical abuse, such as hitting 
and scratching of staff members, other residents, or 
family. This also included sexual abuse of staff members, 
such as inappropriate touching. The increase in physical 
abuse may be correlated to the increase in unrealistic 
fears. Fear can provoke many reactions, and many times 
Alzheimer's disease patients respond physically due to 
their inability to adequately communicate, which can be 
interpreted as abuse from the caregiver or family member.
Findings from the current study imply that the 
variable of psychotropic medications do adversely affect 
the behaviors of the Alzheimer's disease patient. This 
finding may be compared with previous research conducted 
by Lopez et al. (1999) . The study examined the use of 
psychotropic medications and the progression of behaviors 
of the Alzheimer's disease patient and indicated that 
behaviors, such as verbal abuse, physical aggression, and 
wandering, increased with psychotropic medication use. 
Results of the current study supplement these findings 
with a significant relationship between behaviors of the 
Alzheimer's disease patient and psychotropic medication.
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Conclusions
Several conclusions can be derived from the findings 
in this study. This researcher concluded that psychotropic 
medications significantly impact behaviors of the 
Alzheimer's disease patient. Many of the side effects of 
psychotropic medications mimic the symptoms exhibited by 
the Alzheimer's disease patient. It is very difficult to 
distinguish between the drug effects and the natural 
course of the disease process; therefore, it is the hope 
of the current researcher that the study will stimulate 
more research in Alzheimer's disease and the current 
treatments being used to control adverse behaviors.
Although the current researcher believes that 
psychotropic medications increased the negative behaviors 
of the Alzheimer's disease patient, the fact that the 
normal progression of Alzheimer's disease also may 
increase negative behavior and cannot be ignored. As the 
Alzheimer's disease patient progresses through the course 
of the disease, they exhibit many disturbing behaviors. 
These behaviors include wandering, agitation, and physical 
abuse. These are the main reasons Alzheimer's disease 
patients are placed on psychotropic medications. Although 
the findings did not reveal an increase in wandering, they 
did indicate an increase in physical abuse and agitated
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type behaviors. The current researcher found the adverse 
effects outweighed the benefits of psychotropic 
medications in the use of Alzheimer's disease for the 
patients in this study.
Implications for Nursing
A number of implications for nursing science were 
derived from this study. Implications are suggested for 
research, theory, practice, and education.
Research. Limited studies were found that examined 
psychiatric drug therapy and institutionalized Alzheimer's 
disease patients. Therefore, more research is needed to 
determine the effects of psychotropic drug therapy on 
Alzheimer's disease. Additionally, research should 
investigate Alzheimer's disease behaviors and the use of 
medications to control them. The findings from such 
research could impact the care of Alzheimer's disease 
patients in long-term care facilities.
Theory. This study effectively utilized Johnson's 
Behavioral Systems Model as a theoretical framework. The 
concepts of maintenance and balance of functioning through 
the behavioral system, equilibrium, tension, and stressors 
were validated. The concepts of Johnson's model can be 
readily applied to the care of the Alzheimer's disease 
patient as the Alzheimer's disease patient is constantly
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Striving to maintain equilibrium and balance within the 
system. This study adds to the data base of research on 
Alzheimer's disease patients utilizing a systems model as 
a framework.
Practice. In providing care to elders, nurse 
practitioners must be aware of the impact of Alzheimer's 
disease and the medications used to treat behaviors. The 
nurse practitioner could use the results of this study to 
enhance supportive care of the Alzheimer's disease 
patient. In addition, being aware of the negative effects 
of psychotropic medications might assist caregivers in 
anticipation of negative behaviors and risks in these 
patients such as unwanted falls and injuries.
Education. This research study contributed to the 
existing body of nursing knowledge regarding the effects 
of psychotropic medications on Alzheimer's disease 
patients. As the elder population increases, it is 
essential that nurse practitioners be prepared to respond 
to the special needs of the Alzheimer's disease patient. 
The findings of this study indicate Alzheimer's disease 
patients receiving psychotropic medications exhibited an 
increase in negative behaviors. Education of nursing 
students should include information regarding the special 
needs of Alzheimer's disease patients. The health care
66
risks for these patients can be prevented if awareness of 
the detrimental effects of drug therapy is anticipated.
Recommendations
Based on the findings of this study, the following 
recommendations are made :
1. Replication of a similar study with a larger 
sample to evaluate the effects of psychotropic medications 
on institutionalized Alzheimer's disease patients' 
behaviors.
2. Refinement of the Behavioral Assessment for 
Institutionalized Alzheimer's Patients to more fully 
measure the behaviors exhibited.
3. Education of personnel at all levels regarding the 
behaviors of the Alzheimer's disease patient and 
psychotropic medications used to treat them.
4. Comparison of the effects of different 
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Behavioral Assessment for Institutionalized 
Alzheimer's Patients
1. Diagnoses
2. Memory/recall ability 
{code for memory/recall)
______  0. Current season
______  1. Location of room
______  2. Staff names/faces
______  3. That he/she is in a nursing home
______ 4. None of the above are recalled
5. Two or more of the above are recalled
3. Cognitive Skills for daily decision-making 
(made decisions regarding tasks of daily life)
_____  0. Independent--decisions consistent and reasonable
_____  1. Modified independence— some difficulty in new situations only
_____  2. Moderately impaired— decisions poor: cues/supervision required
_____  3. Severely impaired— never/rarely made decisions
4. Indicators of delirium--periodic disordered 
thinking/awareness
(Code for behavior occurring in the last 7 days)
_ 0. Behavior not present
______  1. Behavior present
______  2. Behavior present--appears different from resident's
usual functioning
______  a. Easily distracted (difficulty paying attention: gets
sidetracked)
______  b. Periods of altered perception or awareness of surroundings
(moves lips or talks to someone who is not present/believes he 
is somewhere else : confuses night and day)
______  c. Episodes of disorganized speech (incoherent, nonsensical,
irrelevant, or rambling from subject to subject; loses train of 
thought)
______  d. Periods of restlessness (fidgeting or picking at skin, clothing,
napkins, etc..; frequent position changes; repetitive physical 
movements, wandering, pacing, or calling out)
______  e. Periods of lethargy (sluggishness, staring into space, difficult
to arouse, little body movement)
______  f. Mental function varies over the course of the day (sometimes
better, sometimes worse, behaviors sometimes present, sometimes 
not)
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5. Indicators of depression, anxiety, sad mood 
(Code for indicators observed in the last 30 days)
_____  0. Indicator not exhibited in the last 30 days
_____  1. Indicator of this type exhibited up to 5 days/week
_____  2. Indicator of this type exhibited daily or almost daily
6-7 days/week
______  a. Resident makes negative statements (Nothing matters. Would
rather be dead. What's the use)
______  b. Repetitive questions ("Where do I go. What do I do?")
______  c. Repetitive verbalizations (calling out for help)
______  d. Persistent anger with self or others (easily annoyed, anger at
placement in nursing home, anger at care received)
______  e. Self-deprecation ("I am nothing; I am of no use to anyone")
______  f. Expression of what appears to be unrealistic fears (fear of
being abandoned, left alone, being with others)
______  g. Repetitive health complaints (seeks medical attention, obsessive
concern with body functions)
______  h. Crying, tearfulness
Change in mood
(Resident's mood status has changed as compared to status of 90 days ago)
_____  0. No change
_____  1. Improved
2. Deteriorated
Behavioral symptoms
(Behavioral symptom frequency in last 7 days)
______  0. Behavior not exhibited in last 7 days
______  1. Behavior of this type occurred 1 to 3 days in last 7
days
______  2. Behavior of this type occurred 4 to 6 days, but less
than daily
______  3. Behavior of this type occurred daily
_____  a. Wandering (moved with no rational purpose, seemingly oblivious
to needs or safety)
_____  b. Verbally abusive behavioral symptoms (others were threatened,
screamed at, cursed at)
_____  c. Physically abusive behavioral symptoms (others were hit, shoved,
scratched, sexually abused)
_____  d. Socially inappropriate/disruptive behavioral symptoms (made
disruptive sounds, noisiness, screaming, self-abusive acts, 
sexual behavior, or disrobing in public)
Medications
(List all psychotropic medications the patient is currently on. Included 
scheduled psychotropics and PRN psychotropics)
Medication Name Dose Ordered Route Frequency
Adapted from the Minium Data Set for nursing home residents
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As a graduate student at Mississippi University for Women, 
I will be conducting a research study. In the course of my 
experience in geriatrics, I have become aware of the 
number of people affected by Alzheimer's disease. In my 
proposed research study, I plan to study Alzheimer's 
patients and the behaviors they exhibit. I would like to 
conduct my research at your facility through a chart 
review. There will be no actual patient contact during 
this study. This study is strictly confidential and in no 
way would the facility name or resident name be used. I 
will use a numbering system for identification. As the 
guardian of the residents I am asking your permission to 
conduct my research study in your facility.
Please share this with others in administration and let me 
know if it meets with your approval. If there are any 
questions regarding this study, please feel free to 
contact me. Thanks for your time in reviewing this.
Sincerely,
Mary Beth McKinney, RN, C, BSN
